The global pharmaceutical industry is accelerating; Atorum Group has received orphan drug designation from the US FDA for its SACT-1


HONG KONG, Jul 26, 2022 – (ACN Newswire) – – Population aging is accelerating, pharmaceutical technology is constantly being updated, and the development of the global pharmaceutical industry continues to accelerate. The pharmaceutical market is expected to maintain a growing trend. According Frost and Sullivanthe global pharmaceutical market is expected to reach $1,711.4 billion by 2025.

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic active ingredients to treat diseases with unmet medical needs, particularly in oncology (including orphan indications in oncology) and in infectiology. The pipeline of Aptorum is also enriched by (i) the establishment of drug discovery platforms that enable the discovery of new therapeutic actives, for example the discovery and development of new small molecules and biologics, and the systematic screening of existing approved drug molecules , etc. ; and (ii) the co-development of a new rapid molecular diagnostic technology for the identification and detection of pathogens with Accelerate Technologies Pte Ltdthe marketing arm of that of Singapore science agencyTechnology and Research.

Currently, Aptorum Group R&D pipelines span the ALS family of drugs and the SACT family of drugs, covering indications such as drug-resistant Staphylococcus aureus (including MRSA), Gram-positive cocci, Influenza A, COVID-19, orphan diseases neuroblastoma and other cancers.

Since the beginning of this year, Aptorum Group accelerated its research and development (R&D), with major breakthroughs achieved in several pipelines under development. SACT-1, the Group’s orally administered small molecule drug for the treatment of neuroblastoma, was granted its first patent with the United States Patent and Trademark Office (American PTO) in November 2021 and orphan drug designation by the US Food and Drug Administration (FDA) earlier this year. Meanwhile, the Group completed the Phase I clinical trial of SACT-1 in January this year and announced the final data in May. The data showed SACT-1 to have impressive safety and good tolerability, making further steps of SACT-1 promising.

In addition, earlier in the year, the Group launched a discovery and development platform in oncology and autoimmunity targeting unmet mutations and new biomarkers, focusing on indications such as lung cancer. non-small cell (“NSCLC”) and autoimmune diseases such as lupus, rheumatoid arthritis and inflammatory bowel disease. In the meantime, the Group has also completed a phase I clinical trial for ALS-4, a small molecule anti-virulence drug targeting infections caused by Staphylococcus aureus, including MRSA. In the second quarter of this year, the Group Rapid diagnosis by liquid biopsy of pathogenic infectious diseases (“RPIDD”) has been granted a patent by the American PTOand the Group is spearheading ongoing clinical validation efforts and pre-market readiness for the technology.

Currently, the overall prospects for the development of the biopharmaceutical industry are promising. Aptorum Group actively advances its R&D projects. With its strong R&D capabilities and internal management ability, it is expected to further enhance its business development, expand the business development margin and obtain greater development opportunities in the biopharmaceutical industry. .

Copyright 2022 ACN Newswire. All rights reserved.

© Japan Corporate News, source JCN Press Releases


About Author

Comments are closed.